Company is out of money & hiding things left and right. NO TRANSPARENCY. All upper management is unqualified and has no clue what is going on nor do they care to know. They will continue to run each division into the ground.
Changing to reach and frequency in a division where that does not work (Rare Disease). Products are great, but all new upper management will have patients switch to competitors. Rare is not big pharma.